Patients with triple-negative IBC (TN-IBC) have significantly worse survival outcomes than patients with hormone receptor-positive or HER2-positive IBC [9–11], which necessitates the development of more effective systemic therapy options. The gene discussed is ERBB2; the disease is inflammatory breast carcinoma.